Alnylam Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
FY2009
Asset Breakdown FY2020
Total Assets: $3.41B
Liabilities Breakdown FY2020
Total Liabilities: $2.39B
Asset Breakdown
Total Assets: $3.41B
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $496.6M | 14.6% |
| Accounts Receivable | $102.4M | 3.0% |
| Inventory | $75.2M | 2.2% |
| Property, Plant & Equipment | $465.0M | 13.6% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $2.27B | 66.6% |
Liabilities Breakdown
Total Liabilities: $2.39B
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $52.0M | 2.2% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $2.34B | 97.8% |